focus -WSS

focus

author：leisure time 2025-10-01 17:21:41 - browse：5189

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Some dementia cases could be undiagnosed liver disease

entertainment

knowledge

WSS

A $475,000 price tag for a new cancer drug: crazy or meh?

Even great ERs can’t make up for American health disparities

ARCH Venture Partners is raising $3 billion for a life sciences fund

$1 billion proposal to grow Boston, Massachusetts biotech

Vertex non

State of the Union pitch: Bigger Medicare drug price negotiations

focus

focus

hotspot

In age of alternative facts, a scholarly course on calling out crap

Commercial surrogacy can be ethical, despite pope’s claims

The high cost of giving birth even with insurance

Pregnant women don't need prenatal multivitamins, study concludes

Dobbs anniversary: the lost opportunity of abortion as health care

Medicare drug price negotiation’s day in court

Supreme Court strikes down use of affirmative action

Biden's 'march

Activists slam private health insurers over coverage restrictions

Novo Nordisk to expand supply of Wegovy for U.S. patients

explore

He's 19 months old and has one of the world’s rarest diseases

Change Healthcare: What is it, why does its cyberattack matter?

Ozempic has benefits for kidney disease as well as diabetes

SAMSHA loosens regulations on methadone treatment centers

The untold story of TV’s first prescription drug ad

For AI in health care standards, federal regulators join with industry group

entertainment

knowledge

knowledge

entertainment